Clinical trials: Nonalcoholic Fatty Liver
Vascular Stiffness, Liver Fibroses
Evaluation of the Effect of IHHT on Vascular Stiffness and Elasticity of the Liver Tissue in Patients With MS.
The aim of this study is to assess the effect of interval hypoxy-hyperoxic training (IHHT) on the arterial stiffness and elasticity of the liver tissue in patients with metabolic syndrome and on other components of the metabolic…
- Conditions
- Vascular Stiffness, Liver Fibroses, Metabolic Syndrome, Trimethylamine N-oxyde
- Trial name
- NCT04791397
- Testing
- Interval hypoxic-hyperoxic training (IHHT) using respiratory therapy unit ReOxy., Simulating Interval hypoxic-hyperoxic training (IHHT) using respiratory therapy unit ReOxy.
- Where
- Russia
- Volunteers
- 62 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Nash
Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease
This is a Single -arm, open-label, before-and after exploratory trial of 90 days of Femarelle ® to improve NAFLD and the metabolic syndrome.
- Trial name
- NCT01269320
- Testing
- Femarelle
- Where
- Israel
- Sponsor
- Hadassah Medical Organization
NAFLD
NASH AMPK Exercise Dosing (AMPED) Trial
There is no known cure or regulatory agency approved drug therapy for nonalcoholic fatty liver disease (NAFLD), the leading cause of liver disease worldwide, and its progressive type, NASH.
- Trial name
- AMPED (NCT04987879)
- Testing
- Exercise
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Milton S. Hershey Medical Center
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
The study will assess the efficacy and safety of pegozafermin administered in participants with biopsy-confirmed and clinically confirmed compensated cirrhosis due to MASH .
- Trial name
- NCT06419374
- Testing
- Pegozafermin
- Where
- 330 sites in United States, Argentina and 23 more
- Volunteers
- 1,800 people
- Sponsor
- Hoffmann-La Roche
Liver Diseases, Primary Biliary Cirrhosis
Repeatability and Reproducibility of Multiparametric MRI
This study aims to prospectively assess the repeatability and reproducibility of iron-corrected T1 (cT1), T2*, and hepatic proton density fat fraction (PDFF) quantification with multiparametric MRI using the LiverMultiScan™ (LMS…
- Conditions
- Liver Diseases, Primary Biliary Cirrhosis, Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
- Trial name
- NCT03743272
- Testing
- LiverMultiScan
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Perspectum
Non-Alcoholic Fatty Liver Disease
NASH and Coronary Disease
Although the clinical relationship between NAFLD/NASH and cardiovascular (CV) risk is now well established, there is very little awareness of the hepatic disease and the way it may contribute to increased CV risk in patients seen…
- Trial name
- CORO-NASH (NCT03819283)
- Testing
- Hepatic evaluation
- Where
- France
- Volunteers
- 260 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non Alcoholic Fatty Liver Disease
The Role of Obstructive Sleep Apnea in Children With Fatty Liver Disease
The purpose of this study is to examine whether CPAP therapy can reduce or eliminate hepatic fat accumulation in obese children and adolescents.
- Trial name
- NCT02134522
- Testing
- Continuous positive airway pressure (CPAP).
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Yale University
NAFLD, Hiv
Lifestyle Modification Programme for HIV-infected Individuals With Fatty Liver
Non-alcoholic fatty liver disease (NAFLD) is rising in prevalence, and will likely become the predominant cause of chronic liver disease in HIV-infected individuals.
- Trial name
- NCT03913351
- Testing
- Lifestyle modification
- Where
- Hong Kong
- Volunteers
- 96 people
- Sponsor
- Chinese University of Hong Kong
NASH, NAFLD
Assessment of Fatty Liver With Thermo-acoustic Device
The study will evaluate the accuracy of hepatic steatosis estimation by thermo-acoustic ultrasound with estimation by MRI-PDFF (Proton Density Fat Fraction) .
- Conditions
- NASH, NAFLD, Non-alcoholic Fatty Liver, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT04302051
- Testing
- Thermo-acuostic image acquisition of liver, MRI-PDFF estimation of hepatic fat
- Where
- United States
- Sponsor
- Medical College of Wisconsin
Overweight, Obese
The Effect of Protein-enriched Diet on Body Composition and Appetite
Obesity is a major problem worldwide and current dietary interventions are not proving to be enough to cease the increase in levels of obesity and its detrimental side effects, such as nonalcoholic fatty liver disease (NAFLD).
- Conditions
- Overweight, Obese, Metabolic Syndrome, Non Alcoholic Fatty Liver Disease
- Trial name
- ProteinRich (NCT01634048)
- Testing
- High Protein, low calorie meal replacement
- Where
- United Kingdom
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Nonalcoholic Steatohepatitis (NASH)
Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis
The primary objective of this study is to evaluate the safety and tolerability of firsocostat in adults with nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT02856555
- Testing
- Firsocostat
- Where
- 36 sites in United States
- Volunteers
- 127 people
- Sponsor
- Gilead Sciences
NAFLD, TYPE 2 DIABETES
Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents
The current project is designed as a 30-day pilot trial to demonstrate the safety and tolerability of resveratrol therapy in overweight adolescents to decrease liver fat, and improve insulin sensitivity to prevent type 2 diabetes.
- Conditions
- NAFLD, TYPE 2 DIABETES, METABOLIC SYNDROME
- Trial name
- NCT02216552
- Testing
- Resveratrol
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University of Manitoba
Non-Alcoholic Fatty Liver Disease
Feasibility Study of Deep Learning-based MDixon Quant for Quantitative Assessment of Chemotherapy-induced Fatty Liver
The purpose of this study is to quantitatively assess the changes in liver fat content in cancer patients before and after treatment.
- Trial name
- NCT06735118
- Testing
- Neoadjuvant chemotherapy
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Yunnan Cancer Hospital
Obstructive Sleep Apnea, Non-alcoholic Fatty Liver
Free Walking Exercise in Obstructive Sleep Apnea Patients With Non-alcoholic Fatty Liver
Research evaluating the impact of continuous positive airway pressure (CPAP) \& walking exercise on fatigue severity, liver enzymes and sleeping quality in patients with non-alcoholic fatty liver disease who also have obstructive…
- Trial name
- NCT06508190
- Testing
- continuous positive airway pressure, free walking exercise and continuous positive airway pressure
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Ahram Canadian University
NASH - Nonalcoholic Steatohepatitis With Liver Fibrosis
A Study of EDP-297 in Healthy Subjects
This study is a randomized, double-blind, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of orally administered single and multiple doses of EDP-297 in healthy adult subjects.
- Trial name
- NCT04559126
- Testing
- EDP-297
- Where
- Netherlands
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Vitamin E Dosing Study
This is a multicenter, randomized, double masked, placebo-controlled, parallel treatment groups dosing trial of Vitamin E in adult nonalcoholic fatty liver disease (NAFLD).
- Trial name
- VEDS (NCT04801849)
- Testing
- Vitamin E
- Where
- 9 sites in United States
- Volunteers
- 200 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Nonalcoholic Steatohepatitis
Efficacy and Safety of Viusid in Patients With Nonalcoholic Steatohepatitis
The purpose of the study is to evaluate whether Viusid, a nutritional supplement, in combination with diet and exercise improve the histological results (steatosis, necro-inflammatory activity and fibrosis) in comparison with…
- Trial name
- NCT00509418
- Testing
- Viusid, Hypocaloric Diet with controlled exercise
- Where
- Cuba
- Volunteers
- 60 people
- Sponsor
- Catalysis SL
Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis
Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme
LiverSeek is a fully automated, passive case-finding programme for advanced liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease (MASLD) in primary care.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis, Non-alcoholic Fatty Liver Disease NAFLD, Type 2 Diabetes Mellitus
- Trial name
- LiverSeek (NCT07658755)
- Where
- Spain
- Volunteers
- 3,000 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
NAFLD, Nonalcoholic Fatty Liver
Accurate Point of Care Liver Disease Diagnostics
This research study is being conducted to find out more about techniques to non-invasively evaluate liver disease. The investigators are testing a new technology to evaluate the liver (LiverScope®), and they will compare it to…
- Trial name
- NCT05986916
- Testing
- Liverscope® exam, MR exam, FibroScan® exam (optional)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
Liver Fibrosis
Development of a Novel Biomarker for Liver Fibrosis
The overall aim of this study is to validate a quantitative digital tool for staging liver fibrosis in biopsies from chronic human liver diseases and then evaluate it prospectively in patients.
- Trial name
- NCT02348814
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of California, Los Angeles
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.